CDC says many Americans can now go outside without a mask

 

NEW YORK (AP) – U.S. health officials say fully vaccinated Americans don’t need to wear masks outdoors anymore unless they are in a big crowd of strangers, and those who are unvaccinated can go without a face covering outside in some cases, too.

The Centers for Disease Control and Prevention released the updated guidance Tuesday in yet another carefully calibrated step on the road back to normal from the coronavirus outbreak that has killed over 570,000 people in U.S.

For most of the past year, the CDC had been advising Americans to wear masks outdoors if they are within 6 feet of each other.

The change comes as more than half of U.S. adults have gotten at least one dose of coronavirus vaccine, and more than a third have been fully vaccinated.

“It’s the return of freedom,” said Dr. Mike Saag, an infectious disease expert at the University of Alabama at Birmingham who welcomed the change. “It’s the return of us being able to do normal activities again. We’re not there yet, but we’re on the exit ramp. And that’s a beautiful thing.”

More people need to be vaccinated, and concerns persist about variants and other possible shifts in the epidemic. But Saag said the new guidance is a sensible reward following the development and distribution of effective vaccines and about 140 million Americans stepping forward to get their shots.

The CDC, which has been cautious in its guidance during the crisis, essentially endorsed what many Americans have already been doing over the past several weeks.

The CDC guidance says that fully vaccinated or not, people do not have to wear masks outdoors when they walk, bike or run alone or with members of their household. They also can go maskless in small outdoor gatherings with fully vaccinated people.

But from there, the CDC has differing guidance for people who are fully vaccinated and those who are not.

Unvaccinated people – defined by the CDC as those who have yet to receive both doses of the Pfizer or Moderna vaccine or the one-shot Johnson & Johnson formula – should wear masks at outdoor gatherings that include other unvaccinated people. They also should keep using masks at outdoor restaurants.

Fully vaccinated people do not need to cover up in those situations, the CDC says.

However, everyone should keep wearing masks at crowded outdoor events such as concerts or sporting events, the CDC says.

The agency continues to recommend masks at indoor public places, such as hair salons, restaurants, shopping centers, museums and movie theaters.

Dr. Babak Javid, a physician-scientist at the University of California, San Francisco, said the new CDC guidance is sensible.

“In the vast majority of outdoor scenarios, transmission risk is low,” Javid said.

Javid has favored outdoor mask-wearing requirements because he believes they increase indoor mask-wearing, but he said Americans can understand the relative risks and make good decisions.

“The key thing is to make sure people wear masks indoors” while in public spaces, he said.

He added: “I’m looking forward to mask-free existence.”

“The timing is right because we now have a fair amount of data about the scenarios where transmission occurs,” said Mercedes Carnethon, a professor and vice chair of preventive medicine at Northwestern University’s Feinberg School of Medicine in Chicago.

What’s more, she said, “the additional freedoms may serve as a motivator” for people to get vaccinated.

US recommends ‘pause’ for J&J vaccine over clot reports

WASHINGTON (AP) – The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots.

In a joint statement Tuesday, the Centers for Disease Control and Prevention and the Food and Drug Administration said they were investigating clots in six women that occurred 6 to 13 days after vaccination. The clots were observed in the sinuses of the brain along with reduced platelet counts – making the usual treatment for blood clots, the blood thinner heparin, potentially “dangerous.”

More than 6.8 million doses of the J&J vaccine have been administered in the U.S., the vast majority with no or mild side effects.

U.S. federal distribution channels, including mass vaccination sites, will pause the use of the J&J shot, and states and other providers are expected to follow. The other two authorized vaccines, from Moderna and Pfizer, make up the vast share of COVID-19 shots administered in the U.S. and are not affected by the pause.

CDC’s Advisory Committee on Immunization Practices will meet Wednesday to discuss the cases and the FDA has also launched an investigation into the cause of the clots and low platelet counts.

“Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” Dr. Anne Schuchat, principal deputy director of the CDC, and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a joint statement.

They are recommending that people who were given the J&J vaccine who are experiencing severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after receiving the shot contact their health care provider.

Officials say they also want to educate vaccine providers and health professionals about the “unique treatment” required for this type of clot.

Johnson & Johnson said it was aware of the reports of “thromboembolic events,” or blood clots, but that no link to its vaccine had been established.

“We are aware that thromboembolic events including those with thrombocytopenia have been reported with Covid-19 vaccines,” said Johnson & Johnson in a statement. “At present, no clear causal relationship has been established between these rare events and the Janssen Covid-19 vaccine.”

The J&J vaccine received emergency use authorization from the FDA in late February with great fanfare, with hopes that its single-dose and relatively simple storage requirements would speed vaccinations across the country. Yet the shot only makes up a small fraction of the doses administered in the U.S. as J&J has been plagued by production delays and manufacturing errors at the Baltimore plant of a contractor.

Last week the drugmaker took over the facility to scale up production in hopes of meeting its commitment to the U.S. government of providing about 100 million doses by the end of May.

Only about 9 million of the company’s doses have been delivered to states and are awaiting administration, according to CDC data.

Until now concern about the unusual blood clots has centered on the vaccine from AstraZeneca, which has not yet received authorization in the U.S. Last week, European regulators said they found a possible link between the shots and a very rare type of blood clot that occurs together with low blood platelets, one that seems to occur more in younger people.

The European Medicines Agency stressed that the benefits of receiving the vaccine outweigh the risks for most people. But several countries have imposed limits on who can receive the vaccine; Britain recommended that people under 30 be offered alternatives.

But the J&J and AstraZeneca vaccines are made with the same technology. Leading COVID-19 vaccines train the body to recognize the spike protein that coats the outer surface of the coronavirus. But the J&J and AstraZeneca vaccines use a cold virus, called an adenovirus, to carry the spike gene into the body. J&J uses a human adenovirus to create its vaccine while AstraZeneca uses a chimpanzee version.

The announcement hit U.S. stock markets immediately, with Dow futures falling almost 200 points just over two hours before the opening bell. Shares of Johnson & Johnson dropped almost 3%